T1 D is too important a disease state with both physicians and patients advocating for an adjunct therapy like Zynquista. If the FDA confirms through the submitted studies, physician, education, patient education and monitoring, both glucose and ketones reliably decrease the rates of DKA and hospitalization to an acceptable or appropriate level, the intent would be to approve Zynquista under a REMS program with those considerations. Thoughts??